Recalls of prescription drugs, over-the-counter medications, and compounded pharmaceuticals.
Showing 81–100 of 1,000 recalls
Leading Pharma, LLC
CGMP Deviations; presence of N-nitroso-Furosemide (NNF) above the recommended intake limit.
Xiamen Kang Zhongyuan Biotechnology Co., Ltd.
This recall is being initiated following FDA's recommendation based on certain observations noted during an August 15, 2025, inspection of the manufacturing facility that may bear on product quality.